ReviewExpert opinion on therapeutic targets2021
Emerging therapeutic targets for sepsis.
Review in Expert opinion on therapeutic targets, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07184593 (Validation of a Point-of-care Device for Rapid Bedside Measurement of Circulating Nucleosome Levels in Critically Ill Patients and Study of Its Relevance to Prognostication), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Validation of a Point-of-care Device for Rapid Bedside Measurement of Circulating Nucleosome Levels in Critically Ill Patients and Study of Its Relevance to Prognostication
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Ginsenoside Rg3-enriched red ginseng extract mitigates sepsis by inhibiting platelet-leukocyte aggregates and regulates thrombo-inflammatory pathways.Journal of ginseng research · 2026Article
- The S100A8/A9-NETosis feedback loop in sepsis: potential mechanisms, immune crosstalk, and therapeutic targeting.Frontiers in immunology · 2026Review
- Pro-Dermcidin as an Emerging Regulator of Innate Immunity in Sepsis.International journal of molecular sciences · 2025Review
- Mechanisms of immune suppression in sepsis/shock: one investigator's/lab group's experience (SLB 2024 legacy award presentation).Journal of leukocyte biology · 2025Article
- Molecular Biomarkers and More Efficient Therapies for Sepsis.Biomedicines · 2025Article
- Combined Analysis of Transcriptome and Mendelian Randomization RevealsJournal of inflammation research · 2025Article
- Network Pharmacology, Experimental Validation Explored Kakkalide to Ameliorate Endothelial Cell Dysfunction and Inflammatory Response.Journal of inflammation research · 2025Article
- Dopamine as an endogenous regulator of innate immunity in sepsis.Frontiers in immunology · 2025Review
- Pro-dermcidin and derivatives as potential therapeutics for lethal experimental sepsis.Frontiers in immunology · 2025Article
- Enhancing Early Detection of Sepsis in Neonates through Multimodal Biosignal Integration: A Study of Pulse Oximetry, Near-Infrared Spectroscopy (NIRS), and Skin Temperature Monitoring.Bioengineering (Basel, Switzerland) · 2024Article
- Review
- Connexin 43 and Pannexin 1 hemichannels as endogenous regulators of innate immunity in sepsis.Frontiers in immunology · 2024Review
- Therapeutic potential of procathepsin L-inhibiting and progesterone-entrapping dimethyl-β-cyclodextrin nanoparticles in treating experimental sepsis.Frontiers in immunology · 2024Article
- Development of Procathepsin L (pCTS-L)-Inhibiting Lanosterol-Carrying Liposome Nanoparticles to Treat Lethal Sepsis.International journal of molecular sciences · 2023Article
- Identification of procathepsin L (pCTS-L)-neutralizing monoclonal antibodies to treat potentially lethal sepsis.Science advances · 2023Article
- Oncology Drug Repurposing for Sepsis Treatment.Biomedicines · 2022Review
- Mucin 1 Inhibits Ferroptosis and Sensitizes Vitamin E to Alleviate Sepsis-Induced Acute Lung Injury through GSK3Oxidative medicine and cellular longevity · 2022Article
- Electroacupuncture pre-treatment alleviates sepsis-induced cardiac inflammation and dysfunction by inhibiting the calpain-2/STAT3 pathway.Frontiers in physiology · 2022Article
- A two-decade journey in identifying high mobility group box 1 (HMGB1) and procathepsin L (pCTS-L) as potential therapeutic targets for sepsis.Expert opinion on therapeutic targetsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.